liver-2018-keynote

Page 28

Notes:

allied

academies

Journal of Gastroenterology and Digestive Diseases | Volume 3

May 25-26, 2018 | New York, USA

World Liver Conference 2018

lcoholic hepatitis (AH) is associated with 40-50% mortality

at one month. Liver biopsy is often needed especially

for uncertain clinical diagnosis. Corticosteroids (CS) provide

50% survival benefit with their response evaluable only at

one week. Defects in bioenergetics or mitochondrial oxygen

consumption rate (OCR) in peripheral cells are shown in

systemic diseases. We tested the hypothesis that AH patients

with severe bioenergetics defects will progress to liver failure

and be non-responsive to CS (NRS). After informed consent,

20 mL blood was collected from ALD patients (with or without

AH) and healthy controls. Second 20 mL sample was collected

at one week, from AH patients receiving CS. Monocytes and

neutrophils were isolated within 30 and cellular bioenergetics

and OCR (pmol/min./mcg protein) were obtained using XF96

analyzer (Seahorse Biosciences). Of 78 ALD patients (37 AH)

and 40 healthy controls, OCR differed among 63 ALD patients

for basal, proton leak, non-mitochondrial, and oxidative burst

in monocytes and neutrophils. After controlling for age, WBC,

and MELD score, basal and ATP linked OCR predicted diagnosis

of AH. Bioenergetics inmonocytes improved among responders

but not in NRS on follow up assessment at one week of therapy.

Baseline cellular bioenergetics seems a promising biomarker for

personalizedmedicine in ALDpatients for a) diagnosis of AH and

b) predicting response to CS and outcome on follow up. Data in

larger multicenter population are needed before accepting use

of this novel biomarker in clinical practice.

Speaker Biography

Ashwani K Singal is an Associate Professor of Medicine in Division of Hepatology and

Director of Porphyria Center at the UAB, Birmingham AL. His clinical research interests

include alcohol and non-alcohol fatty liver disease, porphyria, and renal dysfunction

in liver cirrhosis. He has over 110 publications, on editorial board of reputed journals,

and research award committees of the AGA and AASLD. His research is funded

from the Transplant Institute of the UAB, ACG, NIAAA and NIDDK from the NIH, and

pharmaceutical industry.

Ashwani K Singal

University of Alabama at Birmingham, USA

Cellular bioenergetics in patients with alcoholic liver disease